Patient Experience Data is particularly important for the rare disease community because of the inherent limitations in working with small populations, which can cause delays in approval processes. Accessing life-saving or life-prolonging therapy through unlicensed medicine programs is often the only choice. As a result, Patient Experience Data captured as part of Real-World-Evidence (RWE) can…
Read More
Digital Patient Care Transforms Lives.
The pandemic has transformed the way we manage our lives. Over the past 18 months, we’ve learned to do things differently and not do some things at all, like go to the office! Our ability to adapt and virtually communicate is due largely to the significant enabler that is technology. For those with a chronic…
Read More
Managed Access: A Solution with Benefits for Everyone
Managed access programs – also known as compassionate use, early access, and named-patient programs- have clear benefits for patients and physicians. These programs provide an alternative regulatory pathway to help patients access potentially life-altering drugs when they are ineligible for clinical trials or the drug has not been approved in their home country. Historically, the…
Read More
Managed Access: A Missed Opportunity for Orphan Drug Developers and Patients
Product launch planning has changed since my days of working in big pharma. Ten years ago, pharmaceutical marketing professionals focused on ensuring patients could access therapy early, even if they didn’t meet the clinical trial criteria. Early access to therapy, pre-launch and pre-license, offers benefits for all stakeholders. For patients, access to therapy can slow…
Read More